RITALIN-SR TAB 20MG 20 MG
METHYLPHENIDATE HYDROCHLORIDE : 20 MG · DIN 00632775 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is RITALIN-SR TAB 20MG?
RITALIN-SR TAB 20MG 20 MG contains METHYLPHENIDATE HYDROCHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 00632775, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Jul-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RITALIN-SR TAB 20MG used for?
Attention Deficit Hyperactivity Disorder (ADHD); Narcolepsy. Used as part of a total treatment program for ADHD.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00632775 |
|---|---|
| Brand name | RITALIN-SR TAB 20MG |
| Generic / active ingredient | METHYLPHENIDATE HYDROCHLORIDE : 20 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 20 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA III) |
| ATC code | N06BA04 METHYLPHENIDATE |
| AHFS class | 28:20.32 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Jul-2022 |
| Original market date | 1984-12-31 00:00:00 |
How is it administered?
ADHD (6+ years): Individualized dosage. RITALIN SR tablets must be swallowed whole and never crushed or chewed. Periodic re-evaluation for long-term use is required.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text.
How is it supplied?
Not explicitly detailed in provided text (standard Novartis tablets).
Contraindications
Hypersensitivity; anxiety, tension, agitation; thyrotoxicosis; advanced arteriosclerosis; pre-existing cardiovascular disorders; glaucoma; pheochromocytoma; motor tics/Tourette's; MAOI use.
Warnings and precautions
Potential for abuse/dependence. Risk of sudden death in patients with structural cardiac abnormalities. May lower seizure threshold. Risk of serotonin toxicity and peripheral vasculopathy.
What can be used instead?
Other Canadian products sharing ATC code N06BA04 METHYLPHENIDATE. 55 of 103 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441934 |
| ACT METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441942 |
| ACT METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441950 |
| ACT METHYLPHENIDATE ER | 54 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441969 |
| APO-METHYLPHENIDATE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02249324 |
| APO-METHYLPHENIDATE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02249332 |
| APO-METHYLPHENIDATE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02273950 |
| APO-METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452731 |
| APO-METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452758 |
| APO-METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452766 |
Who else supplies METHYLPHENIDATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLPHENIDATE appears in 923 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.